Liquid Biopsy Market - Global Liquid Biopsy Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2030 (By Biomarker, By Source, By Clinical Application, By Indication, By Geographic Coverage and By Company)

Liquid biopsies have gained prominence over conventional cancer diagnostic techniques due to their numerous advantages, such as early prognosis, cost efficiency, and improved patient comfort. With cancer prevalence surging worldwide, this innovative approach provides a ray of hope for patients and healthcare professionals alike.

Key Players in the Market

The report sheds light on some of the major players in the liquid biopsy market, including Guardant Health, Inc., ANGLE plc, Hoffmann-La Roche Ltd., Qiagen N.V., Grail (Illumina, Inc.), Biocept, Inc., Vortex Biosciences, Inc., and MedGenome Inc. These companies have been instrumental in driving advancements in liquid biopsy technology, contributing significantly to the market's growth.

The Rise of Liquid Biopsies

Liquid biopsies involve the analysis of biomarkers present in bodily fluids, primarily blood, to detect the presence of cancer-related genetic mutations and alterations. This non-invasive method offers real-time molecular data, enabling healthcare providers to tailor personalized treatment plans based on a patient's unique genetic profile.

Circulating Free DNA Leading the Way

Among the various biomarkers used in liquid biopsies, circulating free DNA (cfDNA) has emerged as the most preferred biomarker, accounting for 28% of the market value share in 2022. CfDNA offers a non-invasive way to detect genetic alterations associated with cancer, making it a valuable tool for early detection and monitoring of the disease. Other biomarkers, including circulating tumor DNA (ctDNA) are also gaining traction and are expected to contribute significantly to market growth during the forecast period.

Applications and Dominant Indications

Treatment selection and monitoring are the leading application segments in the liquid biopsy market. These applications provide crucial information for tailoring cancer therapies and tracking treatment effectiveness over time. In terms of dominant indications, breast cancer leads the market, capturing over 19% of the market share. The report also highlights promising revenue opportunities in the colorectal cancer indication category.

Ample Opportunities in Pan-Cancer Biopsies

Pan-cancer biopsies have gained popularity for their ability to screen for multiple types of cancer in a single blood draw. In contrast to existing conventional screening programmes that focus on only a limited number of detectable cancers, pan-cancer biopsies offer a more comprehensive approach to cancer screening. The predicted opportunity in this segment is around US$15 Bn by the end of 2032, hinting at the potential for revolutionary changes in cancer detection and early diagnosis.

Non-oncology Indications Surge Ahead

While oncology indications have been the primary focus of liquid biopsies, the report forecasts significant growth in non-oncology indications. In 2022, breast cancer accounted for a market value of more than US$800 Mn, followed by cancers of the lungs and prostate glands. However, the study predicts the strongest rate of growth to occur in the non-oncology indications segment, with a projected growth rate of approximately 17.8% through the end of 2030. This segment includes areas such as transplantation medicine and prenatal screening, highlighting the expanding applications of liquid biopsies beyond oncology.

Regional Analysis and Market Activity

The liquid biopsy market is poised for increased activity in the Asia Pacific region, thanks to rapid developments in diagnostics, a thriving medical tourism industry, accelerating research and development, and government initiatives for cancer awareness. China is expected to lead this growth, with strategic agreements and regulatory approvals playing a pivotal role.

Report Summary

The global liquid biopsy market is on an upward trajectory, driven by its numerous advantages and potential to revolutionize cancer diagnostics and treatment. As the market expands at a CAGR of 17.5%, reaching US$15.5 Bn by 2030, liquid biopsies offer a new ray of hope for early cancer detection and improved patient outcomes. With ongoing research and development, liquid biopsies are set to play an increasingly vital role in the worldwide battle against cancer.